



09/914508

Cyc

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF  
CORRECTION UNDER 37 CFR 1.322  
Docket No. USF-T173CXC1  
Patent No. 6,936,281

on January 4, 2006

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Beerelli Seshi  
Issued : August 30, 2005  
Patent No. : 6,936,281  
For : Human Mesenchymal Progenitor Cell

ATTN: Certificate of Corrections Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Certificate  
JAN 13 2006  
of Correction

REQUEST FOR CERTIFICATE OF CORRECTION  
UNDER 37 CFR 1.322 (OFFICE MISTAKE)

Sir:

A Certificate of Correction (in duplicate) for the above-identified patent has been prepared and is attached hereto.

In the left-hand column below are the column and line numbers where errors occurred in the patent. In the right-hand column are the page and line numbers in the application where the correct information appears.

Patent Reads:

Column 5, line 6:

“stromacell”

Application Reads:

Page 8, line 10:

-- stromal cell --

JAN 17 2006

JAN 17 2006

**Patent Reads:**Column 6, line 8:

“CD45/CD34-mature”

Column 6, line 45:

“hematopoietic”

Column 6, line 45:

“SCID) mice”

Column 8, line 37:

“Simmons, et al,”

Column 11, line 3:

“MPG”

Column 11, line 23:

“isolated MIPCs”

Column 11, line 33:

“engraftment FIGS.”

Column 20, line 66:

“CD34+positive”

Column 24, line 6:“40,000  $\mu$ L”Column 24, line 8:“20,000  $\mu$ L”**Application Reads:**Page 10, lines 4-5:

-- CD45/CD34- mature --

Amendment dated July 25, 2003:

-- hematopoietic --

Amendment dated July 25, 2003:

-- SCID mice --

Page 14, line 9:

-- Simmons, et al., --

Page 18, line 26:

-- MPC --

Amendment dated July 25, 2003:

-- isolated MPCs --

Amendment dated July 25, 2003:

-- engraftment (Figures --

Page 34, line 19:

-- CD34+ positive --

Page 40, line 12:-- 40,000/ $\mu$ L --Page 40, line 13:-- 20,000/ $\mu$ L --

**Patent Reads:**Column 24, line 32:“500 mg/M<sup>2</sup>”Column 27, line 8:

“(AMUMDS,”

Column 27, line 27:

“hMmTRA1 b”

Column 27, line 27:

“GOS2”

Column 27, line 49:

“1 NIB”

Column 29, line 41:

“culture wherein”

Column 30, line 7:

“cells wherein”

Column 30, lines 61-62:

“GvHD) caused”

Column 30, line 67:

“culture wherein”

**Application Reads:**Page 41, line 3:-- 500 mg/m<sup>2</sup> --Page 45, line 30:

-- (AML/MDS, --

Page 46, line 11:

-- hMmTRA1b --

Page 46, line 11:

-- G0S2 --

Page 46, line 31:

-- 1NIB --

Allowed Claim 1:

-- culture, wherein --

Allowed Claim 9:

-- cells, wherein --

Allowed Claim 19:

-- GvHD caused --

Allowed Claim 21:

-- culture, wherein --

JAN 17 2006

JAN 17 2006

Approval of the Certificate of Correction is respectfully requested.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

GPL/ehm

Attachments: Certificate of Correction in duplicate

JAN 17 2006

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,936,281  
APPLICATION NO. : 09/914,508  
ISSUE DATE : August 30, 2005  
INVENTOR(S) : Beerelli Seshi

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 5,

Line 6, "stromacell" should read -- stromal cell --.

Column 6,

Line 8, "CD45/CD34-mature" should read -- CD45/CD34- mature --.

Line 45, "hematopoletic" should read -- hematopoietic --.

Line 45, "SCID) mice" should read -- SCID mice --.

Column 8,

Line 37, "Simmons, et al," should read -- Simmons, et al., --.

Column 11,

Line 3, "MPG" should read -- MPC --.

Line 23, "isolated MIPCs" should read -- isolated MPCs --.

Line 33, "engraftment FIGS." should read -- engraftment (FIGS. --.

Column 20,

Line 66, "CD34+positive" should read -- CD34+ positive --.

Column 24,

Line 6, "40,000  $\mu$ L" should read -- 40,000/ $\mu$ L --.

Line 8, "20,000  $\mu$ L" should read -- 20,000/ $\mu$ L --.

Line 32, "500 mg/M<sup>2</sup>" should read -- 500 mg/m<sup>2</sup> --.

## MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik  
P.O. Box 142950  
Gainesville, FL 32614-2950

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**JAN 17 2006**

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

PATENT NO. : 6,936,281  
APPLICATION NO. : 09/914,508  
ISSUE DATE : August 30, 2005  
INVENTOR(S) : Beerelli Seshi

Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 27,

Line 8, "(AMUMDS," should read -- (AML/MDS, --.  
Line 27, "hMmTRA1 b" should read -- hMmTRA1b --.  
Line 27, "GOS2" should read -- G0S2 --.  
Line 49, "1 NIB" should read -- 1NIB --.

Column 29,

Line 41, "culture wherein" should read -- culture, wherein --.

Column 30,

Line 7, "cells wherein" should read -- cells, wherein --.  
Lines 61-62, "GvHD) caused" should read -- GvHD caused --.  
Line 67, "culture wherein" should read -- culture, wherein --.

**MAILING ADDRESS OF SENDER:**

Saliwanchik, Lloyd & Saliwanchik  
P.O. Box 142950  
Gainesville, FL 32614-2950

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

**JAN 17 2006**

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,936,281  
APPLICATION NO. : 09/914,508  
ISSUE DATE : August 30, 2005  
INVENTOR(S) : Beerelli Seshi

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 5,

Line 6, "stromacell" should read -- stromal cell --.

Column 6,

Line 8, "CD45/CD34-mature" should read -- CD45/CD34- mature --.

Line 45, "hematopoletic" should read -- hematopoietic --.

Line 45, "SCID) mice" should read -- SCID mice --.

Column 8,

Line 37, "Simmons, et al," should read -- Simmons, et al., --.

Column 11,

Line 3, "MPG" should read -- MPC --.

Line 23, "isolated MIPCs" should read -- isolated MPCs --.

Line 33, "engraftment FIGS." should read -- engraftment (FIGS. --.

Column 20,

Line 66, "CD34+positive" should read -- CD34+ positive --.

Column 24,

Line 6, "40,000  $\mu$ L" should read -- 40,000/ $\mu$ L --.

Line 8, "20,000  $\mu$ L" should read -- 20,000/ $\mu$ L --.

Line 32, "500 mg/M<sup>2</sup>" should read -- 500 mg/m<sup>2</sup> --.

**MAILING ADDRESS OF SENDER:**

Saliwanchik, Lloyd & Saliwanchik  
P.O. Box 142950  
Gainesville, FL 32614-2950

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

**JAN 17 2006**

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

PATENT NO. : 6,936,281  
APPLICATION NO. : 09/914,508  
ISSUE DATE : August 30, 2005  
INVENTOR(S) : Beerelli Seshi

Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 27,

Line 8, "(AMUMDS," should read -- (AML/MDS, --.  
Line 27, "hMmTRA1 b" should read -- hMmTRA1b --.  
Line 27, "GOS2" should read -- G0S2 --.  
Line 49, "1 NIB" should read -- 1NIB --.

Column 29,

Line 41, "culture wherein" should read -- culture, wherein --.

Column 30,

Line 7, "cells wherein" should read -- cells, wherein --.  
Lines 61-62, "GvHD) caused" should read -- GvHD caused --.  
Line 67, "culture wherein" should read -- culture, wherein --.

**MAILING ADDRESS OF SENDER:**

Saliwanchik, Lloyd & Saliwanchik  
P.O. Box 142950  
Gainesville, FL 32614-2950

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

**JAN 17 2006**